RBC Capital Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $66
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has initiated coverage on CG Oncology with an Outperform rating and set a price target of $66.
September 23, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on CG Oncology with an Outperform rating and a price target of $66, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $66 by RBC Capital suggests a positive sentiment towards CG Oncology's stock. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100